Seeing more clearly
Coming soon: Greater online access for pharmacists to pathology and diagnostic imaging reports, a crucial boost for patient safety.
Early elixirs: Amphetamine
From wonder drug to scourge. The synthesis of amphetamine has had a profound effect on society as well as attitudes towards drugs.
From its use...
Final CVAS stock order due this week as COVID-19 funding deadline...
From 1 October 2026, COVID-19 vaccination will move from its pandemic-era funding model onto the NIPVIP program.
Vyvanse® (lisdexamfetamine dimesilate) for treatment of adults with ADHD
Vyvanse® (lisdexamfetamine dimesilate) for treatment of adults with ADHD: PBS listed from 1 February 20211,2
What went right (and wrong) with Australia’s COVID-19 response?
COVID-19 enquiry criticises delays involving pharmacists in rollout, calling for urgent harmonisation of vaccine scope.
Helping patients manage persistent pelvic pain
Often complex, undiagnosed pelvic pain can leave patients in awful limbo. Pharmacists can help them understand what drives pain.
